- Friday | 09 Apr, 2021
- Hina Aslam, Ubaid ur Rehman Zia
- Policy Review/Analyses
Introduction: COVID-19 has disturbed almost every sector as well as associated activities across the globe, imposed partial and full lockdowns, limited the travelling and transportation services and forced people to maintain physical distancing. Although many countries have limited the infection rate, the pandemic still looms large across the globe. The resulting impacts appear to be even more catastrophic that will force people to extreme poverty, food insecurity, health and educational crisis, etc. Preventive measures taken by economies have limited the impact of the pandemic but still, the use of vaccines has been identified as the most critical aspect to get countries back on track, especially the low and middle-income countries. An efficient distribution and supply chain in middle-income and high-income countries may save up to 61% and 33% of subsequent deaths respectively (Peters and Hartley 2020). Hence, developing and supplying vaccines is amongst the topmost global priority. As of today, many vaccines are commercially available and have achieved regulatory approvals. Hence, the pharmaceutical companies, manufacturers, and distributors have to face significant logistic challenges to ensure their effective transfer and storage.